CGT
SAGE

Capital Guardian Trust’s Sage Therapeutics SAGE Stock Holding History

Capital Guardian Trust’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		$22.4M Buy
+122,251
New +$20.9M 0.3% 111

Other funds holding SAGE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Capital Guardian Trust's SAGE Position: Q2 2019 in Review

Capital Guardian Trust opened a new position in Sage Therapeutics (SAGE) in Q2 2019: 122,251 shares worth $22.4M. The stake represents 0.3% of the portfolio and ranks #111 among its holdings.

272 funds tracked by Wall St. Rank hold SAGE as of Q2 2019.

  • Capital Guardian Trust held 122,251 shares of Sage Therapeutics worth $22.4M as of Q2 2019.
  • Sage Therapeutics was a new Capital Guardian Trust position in Q2 2019.
  • Sage Therapeutics made up 0.3% of Capital Guardian Trust's portfolio in Q2 2019, its #111 holding.
  • 272 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2019.

Based on Capital Guardian Trust's 13F filing for Q2 2019, filed 14 Aug 2019.